Table 1

Observed crude point prevalence and iSPR of prespecified comorbidities among patients in the PBC population or the PBC-pruritus subpopulation relative to the respective non-case population

ComorbidityPBC population
(N=1963)
PBC-pruritus subpopulation
(N=139)
Non-case population (N=10 245 592)*
%iSPR (95% CI)†%iSPR (95% CI)†%
PBC symptoms of interest
 Diarrhoea9.32.38 (2.05 to 2.75)13.73.73 (2.25 to 5.83)3.1
 Pruritus6.83.24 (2.71 to 3.84)N/AN/A1.5
 UTI13.81.37 (1.21 to 1.54)13.01.36 (0.81 to 2.15)6.6
Prevalent psychiatric and other conditions affecting QoL
 Cognitive impairment3.11.00 (0.77 to 1.29)4.31.77 (0.65 to 3.85)1.7
 Depression or anxiety21.31.09 (0.99 to 1.20)28.11.46 (1.04 to 2.00)15.9
 Fatigue19.91.51 (1.36 to 1.66)26.62.10 (1.48 to 2.90)10.4
 Sleep-related issues6.91.18 (0.99 to 1.40)14.42.58 (1.58 to 3.99)4.4
Liver and autoimmune conditions
 Autoimmune hepatitis9.5151.31 (130.40 to 174.62)12.2218.07 (127.03 to 349.15)0.03
 Autoimmune thyroid disease3.02.09 (1.59 to 2.70)4.32.92 (1.07 to 6.36)1.0
 Raynaud’s syndrome2.97.75 (5.87 to 10.04)2.97.72 (2.10 to 19.75)0.2
 Rheumatoid arthritis6.32.89 (2.40 to 3.45)5.02.58 (1.04 to 5.31)1.2
 Sjögren’s syndrome5.811.64 (9.60 to 13.98)11.525.20 (14.40 to 40.93)0.2
 SLE2.44.91 (3.60 to 6.52)1.42.95 (0.36 to 10.67)0.3
  • *N for the non-case population (N=10 245 592), relates to the comparison versus the PBC population not vs the PBC-pruritus population (N=9 984 009).

  • †Compared with non-case population.

  • CI, confidence interval; iSPRs, indirect age-sex standardised prevalence ratios; N/A, not applicable; PBC, primary biliary cholangitis; QoL, quality of life; SLE, systemic lupus erythematosus; UTI, urinary tract infection.